130 related articles for article (PubMed ID: 38011912)
1. Risk of ischemic stroke associated with direct oral anticoagulants discontinuation on patients with non-valvular atrial fibrillation.
Álvaro Thomsen T; Mesa Guadalupe J; Huerta C; de Burgos A; Cea Soriano L
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5733. PubMed ID: 38011912
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Nadkarni A; Shank TC
BMC Cardiovasc Disord; 2019 Jun; 19(1):142. PubMed ID: 31195999
[TBL] [Abstract][Full Text] [Related]
3. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity.
Dhamane AD; Ferri M; Keshishian A; Russ C; Atreja N; Gutierrez C; Emir B; Yuce H; Di Fusco M
Adv Ther; 2023 Mar; 40(3):887-902. PubMed ID: 36527598
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study.
Lawal OD; Aronow HD; Shobayo F; Hume AL; Taveira TH; Matson KL; Zhang Y; Wen X
Circulation; 2023 Mar; 147(10):782-794. PubMed ID: 36762560
[TBL] [Abstract][Full Text] [Related]
6. Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database.
Khachatryan A; Doobaree IU; Spentzouris G; Gusto G; Zawaneh Y; Mughal F; Anastassopoulou A; Manu M; Fay M
Adv Ther; 2023 Feb; 40(2):504-520. PubMed ID: 36399317
[TBL] [Abstract][Full Text] [Related]
7. Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study.
Jaksa A; Gibbs L; Kent S; Rowark S; Duffield S; Sharma M; Kincaid L; Ali AK; Patrick AR; Govil P; Jonsson P; Gatto N
BMJ Open; 2022 Oct; 12(10):e064662. PubMed ID: 36253039
[TBL] [Abstract][Full Text] [Related]
8. Comparing Efficacy and Safety Between Patients With Atrial Fibrillation Taking Direct Oral Anticoagulants or Warfarin After Direct Oral Anticoagulant Failure.
Hsieh MT; Liu CH; Lin SH; Lin PY; Chang YM; Wang CM; Chen CH; Sung PS
J Am Heart Assoc; 2023 Dec; 12(23):e029979. PubMed ID: 38038171
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Safety and Effectiveness of Four Direct Oral Anticoagulants in Japanese Patients with Nonvalvular Atrial Fibrillation Using Real-World Data.
Enomoto A; Mano Y; Kawano Y; Nishikawa T; Aoyama T; Sasaki Y; Nagata M; Takahashi H
Biol Pharm Bull; 2021; 44(9):1294-1302. PubMed ID: 34471057
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States.
Baker CL; Dhamane AD; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Menges B; Lin J; Nadkarni A
Adv Ther; 2019 Jan; 36(1):162-174. PubMed ID: 30499067
[TBL] [Abstract][Full Text] [Related]
11. Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation.
Jansson M; Själander S; Sjögren V; Björck F; Renlund H; Norrving B; Själander A
J Thromb Thrombolysis; 2023 Apr; 55(3):415-425. PubMed ID: 36607464
[TBL] [Abstract][Full Text] [Related]
12. Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m
O'Kane CP; Avalon JCO; Lacoste JL; Fang W; Bianco CM; Davisson L; Piechowski KL
Pharmacotherapy; 2022 Feb; 42(2):112-118. PubMed ID: 34820876
[TBL] [Abstract][Full Text] [Related]
13. Ischemic Stroke and Systemic Embolism Among One-and-Done Direct Oral Anticoagulant Users with Non-valvular Atrial Fibrillation.
Alberts M; Zhdanava M; Pilon D; Caron-Lapointe G; Lefebvre P; Bookhart B; Kharat A
Adv Ther; 2023 May; 40(5):2339-2354. PubMed ID: 36947331
[TBL] [Abstract][Full Text] [Related]
14. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL
J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban.
Lip GYH; Pan X; Kamble S; Kawabata H; Mardekian J; Masseria C; Phatak H
PLoS One; 2018; 13(4):e0195950. PubMed ID: 29709012
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: A systematic review and meta-analysis of 92 studies.
Archontakis-Barakakis P; Li W; Kalaitzoglou D; Tzelves L; Manolopoulos A; Giannopoulos S; Giamouzis G; Giannakoulas G; Batsidis A; Palaiodimos L; Ntaios G; Lip GYH; Kokkinidis DG
Br J Clin Pharmacol; 2022 Nov; 88(11):4663-4675. PubMed ID: 35853612
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study.
Kjerpeseth LJ; Selmer R; Ariansen I; Karlstad Ø; Ellekjær H; Skovlund E
PLoS One; 2019; 14(8):e0221500. PubMed ID: 31449560
[TBL] [Abstract][Full Text] [Related]
18. Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis.
Amin A; Keshishian A; Hines DM; Dina O; Le H; Rosenblatt L; Liu X; Zhang Q; Vo L
Curr Med Res Opin; 2022 Dec; 38(12):2131-2140. PubMed ID: 35993487
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study.
Dawwas GK; Dietrich E; Cuker A; Barnes GD; Leonard CE; Lewis JD
Ann Intern Med; 2021 Jul; 174(7):910-919. PubMed ID: 33780291
[TBL] [Abstract][Full Text] [Related]
20. Gene polymorphism as a cause of hemorrhagic complications in patients with non-valvular atrial fibrillation treated with oral vitamin K-independent anticoagulants.
Abdrakhmanov A; Shaimerdinova A; Suleimen Z; Abildinova S; Albayev R; Tuyakova G; Rib E; Beysenbayeva A; Kabduyeva G; Bekbossynova M
Ther Adv Cardiovasc Dis; 2024; 18():17539447241249886. PubMed ID: 38801157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
